Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7456 to 7470 of 7707 results

  1. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    29 July 2014

  2. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Technology appraisal guidance
    Published
    16 December 2021

  3. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  4. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  5. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued [GID-TA10047]

    Technology appraisal guidance
    Discontinued

  6. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued [GID-TA10045]

    Technology appraisal guidance
    Discontinued

  7. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  8. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued [GID-TAG300]

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued [GID-TAG278]

    Technology appraisal guidance
    Discontinued

  10. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

    Technology appraisal guidance
    Discontinued

  11. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    In development [GID-TA11357] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  13. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued [GID-TA10242]

    Technology appraisal guidance
    Discontinued

  14. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued [GID-TA11209]

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    In development